Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
AmerisourceBergen Corp. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AmerisourceBergen Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Valuation Ratios
AmerisourceBergen Corp. | Abbott Laboratories | Cigna Group | CVS Health Corp. | Elevance Health Inc. | Humana Inc. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | Health Care Equipment & Services | Health Care | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||
Current share price (P) | ||||||||||||||
No. shares of common stock outstanding | ||||||||||||||
Growth rate (g) | ||||||||||||||
Earnings per share (EPS) | ||||||||||||||
Next year expected EPS | ||||||||||||||
Operating profit per share | ||||||||||||||
Sales per share | ||||||||||||||
Book value per share (BVPS) | ||||||||||||||
Valuation Ratios (Price Multiples) | ||||||||||||||
Price to earnings (P/E) | ||||||||||||||
Price to next year expected earnings | ||||||||||||||
Price-earnings-growth (PEG) | ||||||||||||||
Price to operating profit (P/OP) | ||||||||||||||
Price to sales (P/S) |
Based on: 10-K (reporting date: 2022-09-30).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
---|---|---|---|---|---|---|---|
Price to earnings (P/E) | |||||||
Price to operating profit (P/OP) | |||||||
Price to sales (P/S) | |||||||
Price to book value (P/BV) |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | AmerisourceBergen Corp. P/S ratio increased from 2020 to 2021 and from 2021 to 2022. |
Price to Earnings (P/E)
Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Net income (loss) attributable to AmerisourceBergen Corporation (in thousands) | |||||||
Earnings per share (EPS)2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/E ratio4 | |||||||
Benchmarks | |||||||
P/E Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
P/E Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/E Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
EPS = Net income (loss) attributable to AmerisourceBergen Corporation ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Price to Operating Profit (P/OP)
Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Operating income (loss) (in thousands) | |||||||
Operating profit per share2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/OP ratio4 | |||||||
Benchmarks | |||||||
P/OP Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
P/OP Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/OP Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Price to Sales (P/S)
Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Revenue (in thousands) | |||||||
Sales per share2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/S ratio4 | |||||||
Benchmarks | |||||||
P/S Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
P/S Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/S Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | AmerisourceBergen Corp. P/S ratio increased from 2020 to 2021 and from 2021 to 2022. |
Price to Book Value (P/BV)
Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | |||||||
Selected Financial Data (US$) | |||||||
Total AmerisourceBergen Corporation stockholders’ equity (deficit) (in thousands) | |||||||
Book value per share (BVPS)2 | |||||||
Share price1, 3 | |||||||
Valuation Ratio | |||||||
P/BV ratio4 | |||||||
Benchmarks | |||||||
P/BV Ratio, Competitors5 | |||||||
Abbott Laboratories | |||||||
Cigna Group | |||||||
CVS Health Corp. | |||||||
Elevance Health Inc. | |||||||
Humana Inc. | |||||||
Intuitive Surgical Inc. | |||||||
Medtronic PLC | |||||||
UnitedHealth Group Inc. | |||||||
P/BV Ratio, Sector | |||||||
Health Care Equipment & Services | |||||||
P/BV Ratio, Industry | |||||||
Health Care |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
BVPS = Total AmerisourceBergen Corporation stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.